Microfluidic Formulation of DNA-Loaded Multicomponent Lipid Nanoparticles for Gene Delivery


Authors: E. Quagliarini, S. Renzi, L. Digiacomo, F. Giulimondi, B. Sartori, H. Amenitsch, V. Tassinari, L. Masuelli, R. Bei, L. Cui, J. Wang, A. Amici, C. Marchini, D. Pozzi, and G. Caracciolo

Journal:

DOI: https://doi.org/10.3390/pharmaceutics13081292

Publication - Abstract

August 19, 2021

DNA Nucleic Acid Lipid Nanoparticles Oncology
With recent successes reflected in literature on mRNA delivery using LNPs, scientists from the University of Rome set out to investigate whether that success can be achieved with plasmid DNA delivery using LNPs (pDNA-LNPs). Authors Quagliarini et al. 2021 synthesized pDNA-LNPs using the NanoAssemblr’s tunable microfluidic technology and the impact of characteristics such as size and composition, and process parameters such as total flow rate (TFR) on in vitro transfection efficiencies were assessed. As a result, the paper illustrates small-sized homogenous pDNA-LNPs are capable of a higher transfection efficiency with lower cytotoxicity in three cell lines when compared to the conventional transfection agent Lipofectamine™ 3000. In vitro validation of the pDNA-LNPs in the study showcases precise control over composition through manipulation of TFRs and addition of PEGylation built into the bottom-up approach of NanoAssemblr® technology. Given this article’s assessment of pDNA-LNP physiochemical characteristics, further research can be conducted to accelerate the development of DNA-based vaccines, cancer immunotherapies, and gene therapies.

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Jan 28, 2021
Vaccines

An Update on Self-Amplifying mRNA Vaccine Development

A.K. Blakney, S. Ip. and A.J. Geall

Vaccines Nucleic Acid Lipid Nanoparticles mRNA
This review will explore the four major pillars required for design and development of an saRNA vaccine: Antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)). We report on the major innovations, preclinical a...
Read More


Publication - Abstract

Jul 16, 2016
Molecular Therapy Nucleic Acids

Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo.

G. Basha, M. Ordobadi, W.R. Scott, A. Cottle, Y. Liu, H. Wang and P.R. Cullis

siRNA Nucleic Acid Lipid Nanoparticles Skeletal Disorders

Sclerostin is a protein secreted by osteocytes that is encoded by the SOSTgene; it decreases bone formation by reducing osteoblast differentiation through inhibition of the Wnt signaling pathway.

Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up